Autopsy report · NCT05983367
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Cause of deathFutility
“At the time of the primary analysis, results did not meet the primary endpoint”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 6 months before it stopped.
- 76 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Inspirna, Inc.
- Sponsor type
- Industry
- Conditions
- Colorectal Cancer; Metastatic Colon Cancer
- Interventions
- Ompenaclid; Placebo; Bevacizumab; FOLFIRI regimen
- Participants
- 76
- Sites
- 28
- Countries
- Belgium, France, Spain
Trials that died the same way
- PleuraSeal Pivotal Study (US)
“Interim analysis results were not supportive of primary endpoint” - A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.
“Primary endpoint measure not suitable for evaluation” - Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
“The study was terminated as its Part A did not meet the primary endpoint.” - Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
“primary endpoint was not met”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.